戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ty stimulatable by the inhibitory subunit of cGMP phosphodiesterase.
2  sites on G alpha t with the effector enzyme cGMP phosphodiesterase.
3  degeneration caused by a defective opsin or cGMP phosphodiesterase.
4 protein transducin, which in turn stimulates cGMP phosphodiesterase.
5 or the gene encoding the beta-subunit of the cGMP phosphodiesterase.
6 pigment, rhodopsin, and the effector enzyme, cGMP phosphodiesterase.
7 sing it to bind GTP and stimulate the enzyme cGMP phosphodiesterase.
8 ntly after transducin binds to its effector, cGMP phosphodiesterase.
9 es the phosphorylation profile of a putative cGMP-phosphodiesterase.
10 D sulindac that has been reported to inhibit cGMP phosphodiesterases.
11                                          Rod cGMP phosphodiesterase 6 (PDE6) is a key enzyme of the p
12 es the effector enzyme of phototransduction, cGMP phosphodiesterase 6 (PDE6).
13 P as bait we identified the delta subunit of cGMP phosphodiesterase 6 (PDE6delta) as a novel hIP-inte
14 ed rhodopsin or more efficient activation of cGMP phosphodiesterase 6 by G alpha(t)G2A; alternatively
15  subunit (Galpha(T).GTP) and the cyclic GMP (cGMP) phosphodiesterase 6 (PDE6), which stimulates cGMP
16 etinitis pigmentosa (RP) is due to defective cGMP phosphodiesterase-6 (PDE6).
17                   Our study reveals that rod cGMP phosphodiesterase, a farnesylated protein, is absen
18                                          Rod cGMP-phosphodiesterase, a key enzyme in visual transduct
19 nd to reduce the Ca2+ concentrations through cGMP phosphodiesterase activation as already known.
20 ation, rhodopsin-transducin (G(t)) coupling, cGMP phosphodiesterase activity, and slower formation of
21 n vitro is less than the light/GTP-activated cGMP phosphodiesterase activity.
22 tly bind the bilin phycocyanobilin via their cGMP phosphodiesterase/adenyl cyclase/FhlA (GAF) domains
23 cysteine-based thioether linkages within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain.
24 r the N terminus to one conserved within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain.
25 , and molecular modeling of the Te-PixJ GAF (cGMP phosphodiesterase/adenyl cyclase/FhlA) domain assem
26  bring together the PAS (Per-ARNT-Sim), GAF (cGMP phosphodiesterase/adenyl cyclase/FhlA), and PHY (ph
27 olution structure of the chromophore-binding cGMP phosphodiesterase/adenylcyclase/FhlA (GAF) domain f
28 ines and a hairpin protrusion connecting the cGMP phosphodiesterase/adenylyl cyclase/FhlA (GAF) and p
29 ture of photoconversion for the photosensing cGMP phosphodiesterase/adenylyl cyclase/FhlA (GAF) domai
30 ytochromobilin chromophore buried within the cGMP phosphodiesterase/adenylyl cyclase/FhlA (GAF) domai
31  states following studies of the 23-kDa GAF (cGMP phosphodiesterase/adenylyl cyclase/FhlA) domain fra
32 entially comprised of Period/ARNT/Sim (PAS), cGMP-phosphodiesterase/adenylyl cyclase/FhlA (GAF), and
33 -cGMP or by MY-5445 (a specific inhibitor of cGMP phosphodiesterase) alone suggest that NO increases
34 action between the gamma subunit (Pgamma) of cGMP phosphodiesterase and the alpha subunit (Talpha) of
35 ptosyn) and certain derivatives that inhibit cGMP-phosphodiesterases and thereby increase cellular le
36 function, its poor ability to activate PDE6 (cGMP phosphodiesterase) and decreased GTPase activity, a
37 on of G alpha(transducin) with its effector, cGMP phosphodiesterase, and inhibits transducin-mediated
38 ks the lipid modifications found on G(t) and cGMP phosphodiesterase, and the mechanism for membrane a
39                                Rhodopsin and cGMP phosphodiesterase are found in raft and nonraft por
40           Mutations in the rod photoreceptor cGMP phosphodiesterase beta subunit (PDEbeta) gene are f
41 ly demonstrated that 350 bp of the human rod cGMP phosphodiesterase beta-subunit (beta-PDE) gene prom
42 utations in the genes encoding rhodopsin and cGMP phosphodiesterase beta-subunit (PDE-beta) respectiv
43  rod-specific genes, including rhodopsin and cGMP phosphodiesterase beta-subunit, in synergy with oth
44                          The beta-subunit of cGMP-phosphodiesterase (beta-PDE) is a key protein in ph
45 e OSI-461, both of which inhibit cyclic GMP (cGMP)-phosphodiesterases but lack COX-2 inhibitory activ
46 cin mediates signaling between rhodopsin and cGMP phosphodiesterase by transiently binding its gamma
47                    Further evaluation of the cGMP phosphodiesterase demonstrated Michaelis-Menten kin
48 rate photoreceptors leads to activation of a cGMP-phosphodiesterase effector and the generation of a
49 ation of the cyclic guanosine monophosphate (cGMP)-phosphodiesterase enzyme mediating phototransducti
50            PDE10A is a newly identified cAMP/cGMP phosphodiesterase for which mRNA is highly expresse
51 M in rod photoreceptors, it is possible that cGMP phosphodiesterase functions to increase cytoplasami
52 tion of GAP activity by an effector subunit, cGMP phosphodiesterase gamma and in protein folding and
53             The gamma subunit of the retinal cGMP phosphodiesterase (gammaPDE) acts as an inhibitor o
54         Mutations in the beta subunit of the cGMP phosphodiesterase gene (beta PDE) can cause a reces
55  transducin is crucial for the regulation of cGMP phosphodiesterase in retinal photoreceptors.
56 ansducin is a key step for the regulation of cGMP phosphodiesterase in retinal rod outer segments.
57 ted rhodopsin (R*) with the effector enzyme, cGMP phosphodiesterase in vertebrate photoreceptor cells
58 ucin the G-protein that couples rhodopsin to cGMP-phosphodiesterase in the phototransduction cascade.
59 optosis by a mechanism involving cyclic GMP (cGMP) phosphodiesterase inhibition, sustained elevation
60                          Pretreatment with a cGMP phosphodiesterase inhibitor antagonized the anxioge
61                                          The cGMP phosphodiesterase inhibitor M&B 22948 (30 microM) a
62 ls that is enhanced by pretreatment with the cGMP phosphodiesterase inhibitor sildenafil.
63 with cell permeable cGMP derivatives, or the cGMP phosphodiesterase inhibitor sulindac sulfone (exisu
64                                          The cGMP phosphodiesterase inhibitor zaprinast enhanced the
65                                 The specific cGMP phosphodiesterase inhibitor zaprinast reduced the f
66  We have used this natural mutation, and the cGMP phosphodiesterase inhibitor zaprinast, in wild-type
67 gradation with sildenafil, a specific type 5 cGMP phosphodiesterase inhibitor, on flow-mediated dilat
68 tion or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repr
69                                          The cGMP-phosphodiesterase inhibitors and YC-1 increased the
70  transducin (G(t alpha)), interacts with the cGMP phosphodiesterase inhibitory gamma-subunit (Pgamma)
71                             The ratio of the cGMP-phosphodiesterase inhibitory subunit gamma to cone
72 otransduction partners transducin (G(t)) and cGMP phosphodiesterase, it is a peripheral protein of th
73                                          The cGMP phosphodiesterase of rod photoreceptor cells, PDE6,
74     The mammalian multisubunit photoreceptor cGMP phosphodiesterase PDE alpha beta gamma 2 (PDE6 fami
75 of the gamma-subunit of its effector enzyme, cGMP phosphodiesterase (PDE gamma), and another yet unid
76 -displayed arrestin fragments against RP and cGMP phosphodiesterase (PDE) activity inhibition using s
77  PDEdelta was originally copurified with rod cGMP phosphodiesterase (PDE) and shown to interact with
78 it of transducin (Galphat-GTP) activates the cGMP phosphodiesterase (PDE) by binding the inhibitory g
79                                      The rod cGMP phosphodiesterase (PDE) is the G-protein-activated
80                                              cGMP phosphodiesterase (PDE) is the key effector enzyme
81 ing ectopic expression of a nonphotoreceptor cGMP phosphodiesterase (PDE) isozyme PDE5.
82 y, there was a reduction in the level of rod cGMP phosphodiesterase (PDE) proportional to the decreas
83 se is generated by spontaneous activation of cGMP phosphodiesterase (PDE) through a process that does
84                  alphaT*(S43N) activated the cGMP phosphodiesterase (PDE) with a dose-response simila
85 ontrols inactivation of the effector enzyme, cGMP phosphodiesterase (PDE), during turnoff of the visu
86 hown that P gamma, the regulatory subunit of cGMP phosphodiesterase (PDE), is ADP-ribosylated by endo
87 tolerance would be increased activity of the cGMP phosphodiesterase (PDE), which decreases cGMP level
88  monitored rhodopsin-dependent activation of cGMP phosphodiesterase (PDE), wild type arrestin quenche
89 red in cones than in rods to activate 50% of cGMP phosphodiesterase (PDE).
90 or interaction with the effector enzyme, rod cGMP phosphodiesterase (PDE).
91  (GalphatGTPgammaS) activation of bovine rod cGMP phosphodiesterase (PDE).
92 teins: the G protein, transducin (G(t)), and cGMP phosphodiesterase (PDE).
93 etinal cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) is a key regulator of phot
94 cells contain guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) isoforms of the PDE5 and P
95           Cyclic guanosine 5'-monophosphate (cGMP) phosphodiesterase (PDE) regulates the level of cGM
96 lic 3'-5'-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain.
97 The catalytic core of photoreceptor-specific cGMP-phosphodiesterase (PDE) consists of two subunits, P
98                                              cGMP-phosphodiesterase (PDE) is composed of two catalyti
99                                              cGMP-phosphodiesterase (PDE) is the key effector in rod
100               During photoactivation retinal cGMP-phosphodiesterase (PDE) mediates signal transductio
101 ation channel-3 [CNG3], blue-cone opsin, and cGMP phosphodiesterase [PDE]); were evaluated during dif
102 ccompanied by a rapid phosphorylation of the cGMP phosphodiesterase PDE5, an enzyme whose activity is
103                                  Retinal rod cGMP phosphodiesterase (PDE6 family) is the effector enz
104 ein transducin (G(t)) on the effector enzyme cGMP phosphodiesterase (PDE6) at the surface of disk mem
105 the inhibitory gamma subunit (Pgamma) of rod cGMP phosphodiesterase (PDE6) has been reported to turn
106                      We examined the role of cGMP phosphodiesterase (PDE6) in this difference by expr
107                                          The cGMP phosphodiesterase (PDE6) involved in visual transdu
108                                      Retinal cGMP phosphodiesterase (PDE6) is a key enzyme in vertebr
109                                Photoreceptor cGMP phosphodiesterase (PDE6) is the central enzyme in t
110                                Photoreceptor cGMP phosphodiesterase (PDE6) is the effector enzyme in
111                                Photoreceptor cGMP phosphodiesterase (PDE6) is the effector enzyme in
112      The unique feature of rod photoreceptor cGMP phosphodiesterase (PDE6) is the presence of inhibit
113                            The photoreceptor cGMP phosphodiesterase (PDE6) plays a key role in verteb
114  was originally identified as a putative rod cGMP phosphodiesterase (PDE6) subunit in the retina, whe
115 ue to the massive reduction in levels of rod cGMP phosphodiesterase (PDE6) subunits (alpha, beta, and
116  transduction in retinal rod photoreceptors, cGMP phosphodiesterase (PDE6), is a catalytic heterodime
117 l enzyme of the visual transduction cascade, cGMP phosphodiesterase (PDE6), is regulated by its gamma
118 mma) of the photoreceptor G-protein effector cGMP phosphodiesterase (PDE6).
119                         Retinal rod and cone cGMP phosphodiesterases (PDE6 family) function as the ef
120                                Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to
121 e stable assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme.
122 otoreceptor G protein, transducin, activates cGMP-phosphodiesterase (PDE6) by displacing the inhibito
123                                         Cone cGMP-phosphodiesterase (PDE6) is the key effector enzyme
124 to facilitate the stable assembly of retinal cGMP phosphodiesterase, PDE6.
125 o studies, showing that the delta subunit of cGMP phosphodiesterase (PDEdelta), which possesses a hyd
126 ma subunit of the phototransduction effector cGMP phosphodiesterase (PDEgamma).
127 h the gamma subunit of G(talpha)'s effector, cGMP phosphodiesterase (PDEgamma).
128 plex with its effector, the gamma subunit of cGMP phosphodiesterase (PDEgamma).
129                                     Chimeric cGMP phosphodiesterases (PDEs) have been constructed usi
130 sodilator effect is regulated by a family of cGMP phosphodiesterases (PDEs).
131 GMP but modestly inhibited by rolipram and a cGMP phosphodiesterase peak that was sensitive to inhibi
132 by the gamma-subunit of the effector enzyme, cGMP-phosphodiesterase (Pgamma).
133 cally with transducin bound to its effector, cGMP phosphodiesterase, rather than with transducin alon
134 due to a mutation of the rod-specific enzyme cGMP phosphodiesterase, resulting in permanently opened
135 alysis of the Galpha(t)G38D interaction with cGMP phosphodiesterase revealed marked impairment of the
136  gene PDE6B encoding the beta subunit of rod cGMP-phosphodiesterase shows that the cGMP-binding and c
137  analog) or MY-5445 (a specific inhibitor of cGMP phosphodiesterase) suggests that NO induces GFAP vi
138 er inhibitory activity for trypsin-activated cGMP phosphodiesterase than nonphosphorylated P gamma, i
139 t synergistically with a downstream effector cGMP phosphodiesterase to stimulate the GTPase activity
140  joins rhodopsin and the beta subunit of rod cGMP-phosphodiesterase to become the third component of
141                                              cGMP phosphodiesterase type 5 protein is upregulated in
142 nd the factors controlling expression of the cGMP phosphodiesterase type 6 (PDE6) genes, we have char
143  to the cytosolic chaperone delta-subunit of cGMP phosphodiesterase type 6 (PDE6delta).
144 d with the alphabeta subunit (Palphabeta) of cGMP phosphodiesterase, was specifically radiolabeled by
145 on of RGS9-1.Gbeta5L by the effector enzyme, cGMP phosphodiesterase, which is based entirely on the e
146 (dB-cGMP), and of the selective inhibitor of cGMP-phosphodiesterase zaprinast (ZAP), caused an inhibi

 
Page Top